Models of multiple sclerosis: New insights into pathophysiology and repair

Current Opinion in Neurology

Volumn 21, Issue 3, 2008, Pages 242-247

  Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

Author keywords

Autoimmune encephalomyelitis; Demyelination; Multiple sclerosis; Neurodegeneration; Neuroprotection

Indexed keywords

AUTOANTIBODY; HEAT SHOCK PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; B LYMPHOCYTE; CELL DAMAGE; CELL REGENERATION; EXPERIMENTAL MODEL; HUMAN; INNATE IMMUNITY; MACROPHAGE; MITOCHONDRION; MULTIPLE SCLEROSIS; NEUROPROTECTION; PATHOPHYSIOLOGY; REMYELINIZATION; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TISSUE INJURY; TISSUE REPAIR;

ANIMALS; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FREE RADICALS; HUMANS; MITOCHONDRIAL DISEASES; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES;

EID: 43249125212     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3282fee94a     Document Type: Review

References (54)

1. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17:210-218.
2. Betelli E, Pagany M, Weiner HL, et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 2003; 197:1073-1081.
3. Betelli E, Baeten D, Jäger A, et al. Myelin oligodendrocyte glycoproteinspecific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 2006; 116:2393-2402.
4. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest 2006; 116:2385-2392.
5. Lipton HL, Kumar AS, Trottier M. Theiler's virus persistence in the central nervous system of mice is associated with continuous viral replication and a difference in outcome of infection of infiltrating macrophages versus oligodendrocytes. Virus Res 2005; 111:214-223.
6. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol 2007; 17:219-229.
7. Hoftberger R, Aboul-Enein F, Brueck W, et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 2004; 14:43-55.
8. Babbe H, Roers A, Waisman A, et al. Clonal expansion of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192:393-404.
9. Johnson AJ, Suidan GL, McDole J, Pirko I. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology? Int Rev Neurobiol 2007; 79:73-97.
10. Weiss HA, Millward JM, Owens T. CD8(+) T cells in inflammatory demyelinating disease. J Neuroimmunol 2007; 191:79-85.
11. Huseby ES, Liggitt D, Brabb T, et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001; 194:669-676.
12. Cabarrocas J, Bauer J, Piaggio E, et al. Effective and selective immune surveillance of the brain by MHC class I-restricted cytotoxic T lymphocytes. Eur J Immunol 2003; 33:1174-1182.
13. Mars LT, Bauer J, Gross DA, et al. CD8 T cell responses to myelin oligodendrocyte glycoprotein-derived peptides in humanized HLA-A *0201-transgenic mice. J Immunol 2007; 179:5090-5098.
14. Howe CL, Ure D, Adelson JD, et al. CD8+ T cells directed against a viral peptide contribute to loss of motor function by disrupting axonal transport in a viral model of fulminant demyelination. J Neuroimmunol 2007; 188:13-21.
15. Howe CL, Adelson JD, Rodriguez M. Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis 2007; 25:354-359.
16. Tsunoda I, Tanaka T, Terry EJ, Fujinami RS. Contrasting roles for axonal degeneration in an autoimmune versus viral model of multiple sclerosis: When can axonal injury be beneficial? Am J Pathol 2007; 170:214-226.
17. Linington C, Bradl M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988; 130:443-454.
18. Kanter JL, Narayana S, Ho PP, et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006; 12:138-143.
19. Urich E, Gutcher I, Prinz M, Becher B. Autoantibody mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc Natl Acad Sci U S A 2006; 103:18697-18702.
20. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007; 204:2363-2372. In this study the authors describe autoantibodies against neurofascin in a subset of MS patients. In EAE neurofascin antibodies augment disease apparently by functional blockade of nerve conduction through in-vivo binding to neurofascin at the nodes of Ranvier.
21. Hur EM, Youssef S, Haws ME, et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol 2007; 8:74-83.
22. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2003; 294:1731-1735.
23. Chitnis T, Imitola J, Wang Y, et al. Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol 2007; 170:1695-1712.
24. Hohlfeld R, Kerschensteiner M, Meinl E. Dual role of inflammation in CNS disease. Neurology 2007; 68 (Suppl 3):S58-S63.
25. Takahashi K, Prinz M, Stagi M, et al. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med 2007; 4:e124.
26. Piccio L, Buonsanti C, Mariani M, et al. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 2007; 37:1290-1301.
27. Felts PA, Woolston AM, Fernando HB, et al. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain 2005; 128:1649-1666.
28. Marik C, Felts P, Bauer J, et al. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 2007; 130:2800-2815. In this study the authors show close similarities in the immunopathology between a subtype of active MS lesions and those induced experimentally by direct injection of LPS into the white matter. Patterns of microglia activation in the lesions suggest stimulation through innate immunity, involving precipitated fibrin. Tissue damage follows a pattern of hypoxic injury, most likely due to radical-mediated mitochondrial injury.
29. Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007; 204:571-582. This study expands previous reports on the role of fibrin precipitation in neurodegeneration in EAE. It provides clear evidence that fibrin-induced microglia activation can be blocked by interfering with fibrin binding to the Mac-1 receptor. This has a neuroprotective effect in EAE. Thus, fibrin-induced microglia activation can be blocked by a pathway that does not interfere with the clotting cascade.
30. Diestel A, Atkas O, Hackel D, et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med 2003; 198:1729-1740.
31. Forte M, Gold BG, Marracci G, et al. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc Natl Acad Sci U S A 2007; 104:7558-7563. The findings of this study stress the importance of mitochondrial damage in tissue injury in inflammatory demyelinating lesions. When cyclophilin D, a regulator of the mitochondrial permeability transition pore, is blocked tissue injury is profoundly reduced in EAE lesions.
32. Zagari M, Allmeh A, Sanati MH, et al. Relationship between the clinical scoring and demyelination in central nervous system with total antioxidant capacity of plasma during experimental autoimmune encephalomyelitis development in mice. Neurosci Lett 2007; 412:24-28.
33. Quin J, Goswami R, Balabanov R, Dawson G. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res 2007; 85:977-984.
34. Smerjac SM, Bizzozero OA. Cytoskeletal protein carbonylation and degradation in experimental autoimmune encephalomyelitis. J Neurochem. 2007 [Epub ahead of print].
35. Chora AA, Fontoura P, Cunha A, et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clin Invest 2008; 117:438-447. Heme oxygenase is upregulated in EAE lesions in the course of a stress response to tissue injury. Heme-oxygenase deficient animals develop more aggressive EAE, and the disease is ameliorated when heme oxygenase-1 is induced chemically. A similar protective effect is also seen when animals are exposed to low concentrations of carbon monoxide. Thus heme oxygenase-1 appears to be one of the protective factors induced by cell stress within lesions, and stimulation of heme oxygenase-1 may have an anti-inflammatory and neuroprotective effect in diseases such as MS.
36. Stahnke T, Stadelmann C, Netzler A, et al. Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders. J Mol Neurosci 2007; 32:25-37.
37. Qi X, Sun L, Lewin AS, et al. Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Invest Ophthalmol Vis Sci 2007; 48:5360-5370.
38. Smith KJ. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol 2007; 17:230-242.
39. Bechtold DA, Miller SJ, Dawson AC, et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 2006; 253:1542-1551.
40. Black JA, Liu S, Hains BC, et al. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 2006; 129:3147-3149.
41. Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007; 13:1483-1489.
42. Black JA, Liu S, Carrithers M, et al. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 2007; 62:21-33. It has been shown before that treatment of EAE animals with sodium channel blockers has a major protective effect. As these drugs are in use for treatment of epilepsy patients for many years without major side effects, they are very promising neuroprotective agents in MS. This study, however, shows that abrupt discontinuation of treatment in EAE animals leads to a very severe rebound of inflammation within the CNS, which is associated with high mortality of animals. This is a very important observation, which has to be considered in clinical trials of MS patients with sodium channel blockers, which have already been initiated.
43. Stadelmann C, Ludwin S, Tabira T, et al. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005; 128 (Pt 5):979-987.
44. van Noort JM, van Sechel AC, Bajramovic J, et al. A novel candidate autoantigen in multiple sclerosis: aB-crystallin, a small heat shock protein. Nature 1995; 375:798-801.
45. Bajramovic JJ, Lassmann H, VanNoort JM. Expression of alphaB-crystallin in glia cells during lesional development in multiple sclerosis. J Neuroimmunol 1997; 78:143-151.
46. Ousman SS, Tomooka BH, van Noort JM, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007; 448:474-479. This study describes another very important endogenous stress protein, which plays a protective role in inflammatory demyelinating lesions. AlphaB-crystallin is highly expressed in MS lesions. The protein is neuroprotective in EAE experiments. MS patients, however, develop an immunodominant T-cell and antibody reaction to this protein. This indicates, that an important endogenous protective mechanism is inactivated in MS patients through a specific immune response.
47. Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129:3165-3172.
48. Patani R, Balaratnam M, Vora A, Reynolds R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol 2007; 33:277-287.
49. Warrington AE, Bieber AJ, Ciric B, et al. A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res 2007; 85:967-976.
50. Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007; 13:1228-1233. This study describes a new molecular mechanism controlling myelination and remyelination. Blocking this pathway enhances remyelination in EAE lesions and reduces permanent axonal injury and loss. LINGO-1 is a promising new therapeutic target for stimulation of remyelination in EAE and potentially also in MS lesions.
51. Baron Van Evercooren A, Lachapelle F, Nait-Oumesmar B, Pham Dinh D. Promoting myelin repair in disorders such as multiple sclerosis and some types of leukodystrophy: current studies. Rev Neurol (Paris) 2007; 163:523-531.
52. Pluchino S, Zanotti L, Rossi B, et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005; 436:266-271.
53. Einstein O, Fainstein N, Vaknin I, et al. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol 2007; 61:209-218.
54. Matysiak M, Stasiolek W, Jurewics A, et al. Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism. J Neuroimmunol 2008; 193:12-33.